Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Speedy US approval for Amgen’s Lumakras was an embarrassment for Mirati, which has gone quiet as its share price has drifted downwards.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.